Join Veracyte's Spotlight Theater, Sunday at 3:30 p.m. ET at #AACR23 !
Stéphane Champiat, Gustave Roussy, will discuss the importance of tumor immune profiling to improve IO clinical development.
Jerome Galon will share how Veracyte, Inc. Biopharma solutions can help guide drug development.

Are you attending #AACR23 (AACR)? If so, meet with our team at Booth #1701 to learn how Veracyte's Biopharma Services team can help you confidently advance your #oncology and #immunooncology drug development programs.
We look forward to seeing you in Orlando!

Yesterday, we were pleased to announce the publication of preclinical data with a trispecific NK cell engager in acute myeloid leukemia in Nature Biotechnology

Click here 👉 innate-pharma.com/media/all-pres…

Sanofi #InnateImmunity #InnateImmune #Oncology #Cancer #NKcell #CellulesNK #ANKET

Why #gdTcells are awesome, exhibit 3147.

Learn more about ImCheck’s partnership with Leukemia & Lymphoma Society Research TAP by attending this live one-hour virtual discussion panel on January 18, 2023, at 18:00 PM CET/12:00 noon ET/9:00 AM PT/6:00 PM CET
Register @ bit.ly/LLSTAP23

The RHU PIONeeR project announces the completion of a major milestone with 450 patients enrolled in the biomarker part of the study, led by Veracyte, Inc., in early 2023.
#oncology #immunotherapy #NSCLC #PD1 #PD1 L1 #precisiononcology #France2030
More: bit.ly/3IwoNc5
Fabrice Barlesi

#ÉPIDÉMIES 🦠 Il est plus que jamais important de rappeler la nécessité de respecter les #GestesBarrières .

Excellent discussion, as usual, from Dr. Solange Peters at the #ASCOPlenarySeries , showing how vast the immunotherapy (and specifically the #TIGIT ) landscape has become in a relatively short time. #LCSM

Attending #ESMOImmuno22 ?
Don't miss the presentation on the #PIONeeRproject with Fabrice Barlesi today at 14:45 'Comprehensive #biomarkers analysis to predict efficacy of #PD1L1 #ICIs in combination with #chemotherapy : a subgroup analysis of the PIONeeR trial'
#NSCLC #precisiononcology

Three posters showcasing IPH5201 and IPH5301 will be presented at #ESMOio22 .

Learn more: bit.ly/3iutkAs

ESMO - Eur. Oncology

Dr. Miriam Merad, MD, PhD, VP of International Union of Immunological Societies and Director of Lipschultz Precision Immunology Institute, invites you to join IUIS 2023 which brings together 5,000+ immunologists to leverage the connectivity between human health and basic immunology – in South Africa, Africa, and globally: mshs.co/3hzPNM4

Le #Biocluster en #Immunologie Marseille #Immunopole conforte son leadership avec la nomination de Daniel Olive à la présidence de la SFI Immunologie. Félicitations Daniel!
marseille-immunopole.org/communaute/dan… #immunopole

We are glad to share with you the 2 posters on the #PioneerProject presented today at the Society for Immunotherapy of Cancer annual meeting
#SITC2022 #immunotherapy
marseille-immunopole.org/en/mi-live/pio… #immunopole

Veracyte is excited to be at the #SITC2022 conference, taking place Nov. 8–12, 2022 in Boston!
We invite you to meet with our team at Booth 412 and learn more about our Biopharma services to confidently advance every step of oncology drug development programs.

Le #Biocluster en #Immunologie Marseille #Immunopole conforte son leadership avec la levée de fonds record d’@ImcheckThx #NextGenerationImmunology bit.ly/3tvCy24

ImCheck Therapeutics à l’assaut d’une nouvelle génération d’anticancéreux ift.tt/tld6s0m

Congratulation to our founding member @ImcheckThx for this impressive financing!

Le #RHU #ThePIONeeRProject a désormais sa page Linkedin! Abonnez vous pour ne rater aucune information !
linkedin.com/company/rhu-th…

Fabrice Barlesi Aix-Marseille Université AP-HM - Hôpitaux Universitaires de Marseille Inserm CNRS 🌍
AstraZeneca Veracyte Biopharma Services Innate Pharma
@ImcheckThx Centre Leon Berard Institut Paoli-Calmettes (IPC) CHU de Toulouse